Boswellin® Super is obtained from the gum exudate of Boswellia serrata trees commonly known as Frankincense.
Efficacy of Boswellin® Super
Alleviates knee pain in rheumatoid arthritis
Boswellia serrata extract is a traditional remedy for joint health with an anti-inflammatory effect. The effect of Boswellin® Super on reducing knee pain was investigated in a randomized, double-blind, placebo-controlled trial. Patients with knee pain were assigned to receive either Boswellin® Super or placebo as one capsule daily for 8 weeks (Majeed et al., 2016).
Compared with baseline, the Boswellin® Super group patients showed significant improvements in the knee pain parameters such as Visual Analog Scale (VAS), Japanese Knee Osteoarthritis Measure (JKOM), and Western Ontario & Mc Master Universities Osteoarthritis Index (WOMAC) scores after 8 weeks of the intervention. The Boswellin® Super group patients also showed low serum hyaluronic acid levels than the placebo group (Majeed et al., 2016).
Measured values of JKOM total score, WOMAC total score and blood tests
|Item||Unit||Group||Week 0||Week 4||Week 8|
|VAS||mm||Boswellin® Super||68.8 (12.1)||34.4 (23.8)||35.6 (22.3)|
|Placebo||71.8 (10.3)||41.8 (24.2)||39.6 (27.3)|
|JKOM total score||Point||Boswellin® Super||48.3 (13.0)||39.4 (11.0)||38.8 (12.1)|
|Placebo||48.5 (11.8)||39.5 (8.2)||36.4 (6.9)|
|WOMAC total score||Point||Boswellin® Super||23.7 (16.7)||14.3 (13.3)||12.7 (14.2)|
|Placebo||24.0 (15.9)||14.6 (11.4)||9.8 (8.8)|
|Hyaluronic acid||ng/mL||Boswellin® Super||18.8 (14.3)||15.9 (6.4)||18.4 (8.9)|
|Placebo||24.8 (24.8)||50.3 (101.4)||42.9 (66.8)|
|High sensitivity CRP||ng/mL||Boswellin® Super||0.03 (0.03)||0.05 (0.10)||0.04 (0.05)|
|Placebo||0.09 (0.14)||0.04 (0.05)||0.05 (0.07)|
Data expressed as Mean SD
Improve pain and joint function in non-rheumatic osteoarthritis condition
NILIN™ SR is a bilayered tablet formulation containing 272 mg Boswellin® (40% AKBBA) with 250 mg curcumin C3® complex (curcuminoids) and 100 mg gingerol (35%). In a 56 days study with 32 subjects (aged 40-65 years) who are having clinically diagnostic osteoarthritis of the knee, but no other rheumatologic conditions, showed a significant reduction in WOMAC scores in respect to all the three parameters; pain (P<0.0001), stiffness (P<0.0001) and physical disability (P<0.0001). Further, a significant reduction in the pain visual analogue score, improvement in 6-minute walk distance and HsCRP levels were also observed upon the supplementation with NILIN™ SR tablets (twice a day) (Natarajan and Majeed, 2012).